Tiziana Life Sciences to attend LSIF 2025 forum

Tiziana Life Sciences LTD filed a Form 6-K to share that it has been invited to attend the J.P.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Tiziana Life Sciences LTD filed a Form 6-K to share that it has been invited to attend the J.P. Morgan Asset Management Life Science Innovation Forum (LSIF) 2025 in collaboration with KAIMRC. The event will take place on October 1–2, 2025 at the King Saud bin Abdulaziz University for Health Sciences Conference Center in Riyadh, Saudi Arabia.

The company is furnishing a related press release as Exhibit 99.1, noting that this information is being provided for informational purposes and is not deemed filed for liability purposes under U.S. securities laws.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tiziana Life Sciences LTD (TLSA) disclose in this Form 6-K?

The company disclosed that it has been invited to attend the J.P. Morgan Asset Management Life Science Innovation Forum (LSIF) 2025 in collaboration with KAIMRC in Riyadh, Saudi Arabia.

When and where is the Life Science Innovation Forum (LSIF) 2025 mentioned by Tiziana Life Sciences LTD?

The LSIF 2025 is scheduled for October 1–2, 2025 at the King Saud bin Abdulaziz University for Health Sciences Conference Center in Riyadh, Saudi Arabia.

Does this Tiziana Life Sciences LTD (TLSA) Form 6-K include a press release?

Yes. The filing includes a press release as Exhibit 99.1, described as a Tiziana Life Sciences LTD press release dated September 30, 2025.

Is the information in Tiziana Life Sciences LTD’s Exhibit 99.1 considered filed with the SEC?

No. The company states the information in Exhibit 99.1 is being furnished and shall not be deemed filed or subject to Section 18 liabilities of the Securities Exchange Act of 1934.

Who signed this Tiziana Life Sciences LTD (TLSA) Form 6-K?

The Form 6-K was signed on behalf of Tiziana Life Sciences LTD by Keeren Shah, Chief Financial Officer, dated September 30, 2025.

Does this Tiziana Life Sciences LTD Form 6-K describe any financing or earnings results?

No. The Form 6-K focuses on the company’s participation in the LSIF 2025 event and the furnishing of a related press release.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 09/30/2025 - 08:30 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

September 2025

Commission File Number: 001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On September 30, 2025, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing that it has been invited to attend the J.P. Morgan Asset Management, Life Science Innovation Forum (LSIF) 2025 in Collaboration with KAIMRC, taking place October 1–2, 2025, at the King Saud bin Abdulaziz University for Health Sciences Conference Center in Riyadh, Saudi Arabia.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIZIANA LIFE SCIENCES LTD

Date: September 30, 2025	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief Financial Officer

EXHIBIT INDEX

Exhibit No.		Description
99.1		Tiziana Life Sciences LTD Press Release, dated September 30, 2025

Source: View Original Filing on SEC EDGAR